Clinical outcomes after treatment with direct-acting antivirals: not all concern hepatocellular carcinoma risk

作     者：Elton Dajti Federico Ravaioli Davide Festi Antonio Colecchia Elton Dajti;Federico Ravaioli;Davide Festi;Antonio Colecchia

作者机构：Department of Medical and Surgical Sciences(DIMEC)University of BolognaBolognaItaly Unit of GastroenterologyBorgo Trento University Hospital of VeronaVeronaItaly 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2020年第9卷第4期

页      面：505-507页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：hepatocellular sustained treatment 

摘      要：The introduction of direct-acting antivirals(DAAs)has revolutionized the natural history of chronic hepatitis C virus(HCV)infection,as the high rates of sustained virologic response(SVR)have been associated with improved survival in both cirrhotic and noncirrhotic patients(1).However,the risk of hepatocellular carcinoma(HCC)after DAA treatment has been a hot topic in the literature of the last few years,especially after two initial studies reporting unexpectedly high rates of both HCC occurrence and recurrence after SVR(2,3).